">
Sunday, 2 November 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 02 November 2025
News

CEO out after damning sales probe

 Posted 31 October 2025 PM

The spectacular fall from grace for Organon boss Kevin Ali who stepped down from the CEO role over improper sales practices was our top story this week.

Ali walked away with no severance or equity-related retirement benefits after an internal investigation revealed the company, under his stewardship, asked certain wholesalers to buy more of the company's birth control implant than they needed over multiple quarters to enable Organon to meet guidance expectations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (3)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.